| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/03/2011 | WO2011013644A1 Substituted piperidine compound |
| 02/03/2011 | WO2011013639A1 Tablet |
| 02/03/2011 | WO2011013624A1 Indole derivative and pharmacologically acceptable salt thereof |
| 02/03/2011 | WO2011013623A1 Indole derivative and pharmacologically acceptable salt thereof |
| 02/03/2011 | WO2011013592A1 Coated preparation |
| 02/03/2011 | WO2011013496A1 Process for preparation of aphanothece sacrum-originated polysaccharide with reduced trivalent metal content |
| 02/03/2011 | WO2011013494A1 Aqueous composition |
| 02/03/2011 | WO2011013398A1 Compound having high affinity for cd22 molecule and capable of enhancing proliferation of b cells |
| 02/03/2011 | WO2011013359A1 Medicinal composition for iontophoresis |
| 02/03/2011 | WO2011013159A1 Photochemotherapeutic heterocyclic agents having antiproliferative and antineoplastic activity |
| 02/03/2011 | WO2011013110A1 Unit dosage forms of hiv protease inhibitors |
| 02/03/2011 | WO2011013108A1 Polymorphic form of toremifene citrate and process for its preparation |
| 02/03/2011 | WO2011013082A1 Multi-layered, multiple unit pharmaceutical compositions |
| 02/03/2011 | WO2011013077A1 New bicyclic dioxanes, their preparation and their use as fragrant compounds |
| 02/03/2011 | WO2011013040A1 Aptamers which inhibit the activity of the human rad51 protein, and biological uses thereof |
| 02/03/2011 | WO2011013002A1 Condensed pyridine derivatives useful as potent inhibitors of the protein kinase ck2 |
| 02/03/2011 | WO2011012990A2 Improved pharmacokinetics of s-adenosylmethionine formulations |
| 02/03/2011 | WO2011012989A1 S-adenosylmethionine formulations with enhanced bioavailability |
| 02/03/2011 | WO2011012961A1 An improved process for the preparation of clopidogrel bisulfate |
| 02/03/2011 | WO2011012897A1 New combinations for the treatment of asthma |
| 02/03/2011 | WO2011012885A1 Fulvestrant in a dosage of 500mg for the treatment of advanced breast cancer |
| 02/03/2011 | WO2011012883A1 Benzo [e] [1, 3 ] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors |
| 02/03/2011 | WO2011012868A1 Compounds for treatment of inflammation |
| 02/03/2011 | WO2011012816A2 Pharmaceutical formulation |
| 02/03/2011 | WO2011012810A1 2-amino-2-phenyl-alkanol derivatives, preparation thereof, and pharmaceutical compositions containing same |
| 02/03/2011 | WO2011012801A1 Tetrahydroquinoxaline urea derivatives, preparation thereof, and therapeutic use thereof |
| 02/03/2011 | WO2011012800A1 Tetrahydroquinoxaline urea derivatives, preparation thereof, and therapeutic use thereof |
| 02/03/2011 | WO2011012780A1 Use of rosmarinic acid and the derivatives thereof to treat ciguatera |
| 02/03/2011 | WO2011012723A1 Injectable sustained release compositions comprising a pramipexole prodrug |
| 02/03/2011 | WO2011012720A2 Compositions for generating an antigen specific immune response |
| 02/03/2011 | WO2011012713A1 Combination of a chemotherapeutic agent and an inhibitor of the tgf-beta system |
| 02/03/2011 | WO2011012698A2 Phthalocyanine derivative consisting of a mixture of 4 isomers |
| 02/03/2011 | WO2011012674A1 Dihydrobenzoindazoles |
| 02/03/2011 | WO2011012661A1 Pyridine and pyrazine derivatives as protein kinase modulators |
| 02/03/2011 | WO2011012660A1 Antitumor 1,2-diphenylpyrrole compounds and their preparation process |
| 02/03/2011 | WO2011012654A1 Hydroxyasenapine compounds, derivatives thereof and pharmaceutical compositions comprising same |
| 02/03/2011 | WO2011012630A1 Substituted bis-aryl pyrazole amides having terminal primary amide functionalization for treating retroviral diseases |
| 02/03/2011 | WO2011012622A1 Benzoxazinone derivatives for the treatment of glytl mediated disorders |
| 02/03/2011 | WO2011012602A1 Piperidine derivatives and their use to treat obesity, diabetes, dyslipidemia and atherosclerosis |
| 02/03/2011 | WO2011012600A1 Ring-annulated dihydropyrrolo[2,l-a]isoquinolines |
| 02/03/2011 | WO2011012592A1 Dihydropyrimidone amides as p2x7 modulators |
| 02/03/2011 | WO2011012585A1 Mutants pf4 polypeptides exhibiting an increased anti-angiogenic activity |
| 02/03/2011 | WO2011012577A1 Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases |
| 02/03/2011 | WO2011012557A1 Ophthalmic solution for protecting internal structures of the eyeball against uv-a rays or for the treatment of keratoconus with a trans-epithelial cross-linking technique |
| 02/03/2011 | WO2011012540A1 Tricyclic inhibitors of jak |
| 02/03/2011 | WO2011012538A1 Cyclic (aza)indolizinecarboxamides, their preparation and their use as pharmaceuticals |
| 02/03/2011 | WO2011012534A1 Plk inhibitor salts |
| 02/03/2011 | WO2011012527A1 Otamixaban for treatment of elderly and renal impaired non-st elevation myocardial infarction patients |
| 02/03/2011 | WO2011012526A1 Flavanones-containing food compositions |
| 02/03/2011 | WO2011012525A1 Flavanones-containing food compositions |
| 02/03/2011 | WO2011012321A1 Processes for crystallization of rivaroxaban |
| 02/03/2011 | WO2011012312A1 Bladder instillation compositions for treating bladder cancer |
| 02/03/2011 | WO2011012298A1 Agonists and antagonists of human bitter taste receptor tas2r49 and uses thereof |
| 02/03/2011 | WO2011012283A1 Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event |
| 02/03/2011 | WO2011012256A1 Composition comprising alpha-lipoic acid and carnosine for treating the phantom limb syndrome |
| 02/03/2011 | WO2011012075A1 Substituted phenyl piperazinyl aralkylone derivatives and its application for preparing analgesic drugs |
| 02/03/2011 | WO2011011965A1 Luteinising hormone releasing hormone antagonist with hydantoin structure |
| 02/03/2011 | WO2011011886A1 Compositions and methods for treating parkinson's disease |
| 02/03/2011 | WO2011011882A1 Hydroxy fatty acid compounds and uses thereof for disease treatment and diagnosis |
| 02/03/2011 | WO2011011881A1 Pharmaceutical compositions comprising modified fucans for use in the treatment of fibrous adhesions and other disorders |
| 02/03/2011 | WO2011011872A1 Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| 02/03/2011 | WO2011011865A1 Anticancer agents based on amino acid derivatives |
| 02/03/2011 | WO2010144611A3 Antivirals that target transporters, carriers, and ion channels |
| 02/03/2011 | WO2010144336A3 Methods for treating chronic kidney disease |
| 02/03/2011 | WO2010142143A9 Pirfenidone compound, preparation method and use thereof |
| 02/03/2011 | WO2010141724A3 Peptide dicer substrate agents and methods for their specific inhibition of gene expression |
| 02/03/2011 | WO2010140170A4 Topical micro-emulsions for the treatment of rheumatic disorders |
| 02/03/2011 | WO2010136522A3 A piperazine derivative free, or essentially free, of potential genotoxicity, and a process for preparing the same |
| 02/03/2011 | WO2010131192A3 Novel oxazolidinone derivatives and their use as orexin receptor antagonists |
| 02/03/2011 | WO2010129445A3 Topical compositions comprising inorganic particulates and an alkoxylated diphenylacrylate compound |
| 02/03/2011 | WO2010129276A3 PYRO-GLUTAMATE Aβ TARGETING AGENTS |
| 02/03/2011 | WO2010129233A9 Methods of treating bacterial infections using oritavancin |
| 02/03/2011 | WO2010127878A3 Use of thiabendazole and derivatives thereof for the theraphy of neurological conditions |
| 02/03/2011 | WO2010124042A3 Modulators of 5-ht receptors and methods of use thereof |
| 02/03/2011 | WO2010123832A3 2-oxamide inhibitors of phospholipase a2 activity and cellular arachidonate release based on dipeptides and pseudopeptides |
| 02/03/2011 | WO2010123545A3 Angiogenesis inhibitors |
| 02/03/2011 | WO2010119078A9 Indole derivative modulators of the alpha 7 nachr |
| 02/03/2011 | WO2010118298A3 Compositions and methods for bioactive coatings to improve allograft incorporation |
| 02/03/2011 | WO2010115612A3 Pregabalin compositions |
| 02/03/2011 | WO2010115491A3 Piperidine and piperazine derivatives as autotaxin inhibitors |
| 02/03/2011 | WO2010111374A9 Compositions and methods for alleviating skin disorders |
| 02/03/2011 | WO2010111136A9 Aliskiren modulation of neurogenesis |
| 02/03/2011 | WO2010107704A3 Ellipticine compounds for treating obesity |
| 02/03/2011 | WO2010106187A3 Inhibitors of cathepsin s for prevention or treatment of obesity-associated disorders |
| 02/03/2011 | WO2010102281A3 Inhibitors of anaphase promoting complex activity |
| 02/03/2011 | WO2010100650A4 Therapeutic uses of mastic gum fractions |
| 02/03/2011 | WO2010092090A3 Novel salts of sitagliptin |
| 02/03/2011 | WO2010091193A3 Triptolide c-ring derivatives as anticancer agents and immune modulators |
| 02/03/2011 | WO2010090611A3 Taste and odor masked pharmaceutical compositions with high bioavailability |
| 02/03/2011 | WO2010085589A3 Desensitizing drug product |
| 02/03/2011 | WO2010065961A3 Compositions and methods relating to mir-31 |
| 02/03/2011 | WO2010060937A3 Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor |
| 02/03/2011 | WO2010059969A8 Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer |
| 02/03/2011 | WO2010025906A3 Hybrid antimicrobial compounds and their use |
| 02/03/2011 | WO2010003568A8 Topical composition for the treatment of actinic keratosis |
| 02/03/2011 | WO2009142571A8 Phenyl and benzodioxinyl substituted indazoles derivatives |
| 02/03/2011 | WO2009132238A3 Ido inhibitors |
| 02/03/2011 | WO2009132050A9 Auris formulations for treating otic diseases and conditions |
| 02/03/2011 | WO2009042972A9 Fluorinated lipids and methods of use |
| 02/03/2011 | WO2008006204A3 Fibrous calcium pyrophosphate particles and methods of making and using same |